Login to Your Account

Other News To Note

Tuesday, August 23, 2011
Santarus Inc., of San Diego, and Depomed Inc., of Menlo Park, Calif., inked a new commercialization deal for Glumetza (metformin hydrochloride extended-release tablets) under which Santarus will assume broad commercial, manufacturing and regulatory responsibilities to replace a promotion agreement signed in July 2008. The new terms call for Santarus to record revenue from Glumetza sales in the U.S., effective Sept. 1.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription